Company Phytopharm plc London S.E.
Stocks
GB0006869720
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
||
| - GBX | - |
|
| 07-13 | Oil rises as Iran escalation keeps FTSE subdued | AN |
| 07-13 | Ixico notes ending of Huntington's disease programmes | AN |
Business description: Phytopharm plc
Sales by Activity: Phytopharm plc
| Fiscal Period: September | 2021 (GBP) | 2022 (GBP) | 2023 (GBP) | 2024 (GBP) | 2025 (GBP) |
|---|---|---|---|---|---|
Medical Labs & Research | 9.19M | 8.64M | 6.66M | 5.77M | 6.53M |
Geographical breakdown of sales: Phytopharm plc
| Fiscal Period: September | 2021 (GBP) | 2022 (GBP) | 2023 (GBP) | 2024 (GBP) | 2025 (GBP) |
|---|---|---|---|---|---|
United States of America | 1.86M | 2.71M | 3.05M | 2.36M | 2.87M |
United Kingdom | 1.98M | 2.06M | 952K | 1.33M | 1.79M |
Netherlands | 1.25M | 436K | 862K | 742K | 623K |
Denmark | - | - | - | - | 407K |
Switzerland | 3.25M | 2.08M | 816K | 500K | 398K |
Ireland | 482K | 724K | 689K | 557K | 304K |
Other - Europe | 370K | 638K | 293K | 272K | 136K |
Rest of World | - | - | - | - | 6K |
Executive Committee: Phytopharm plc
| Manager | Title | Age | Since |
|---|---|---|---|
Bram Goorden
CEO | Chief Executive Officer | 53 | 2024-08-18 |
Grant Nash
DFI | Director of Finance/CFO | 50 | 2019-08-20 |
Mark Austin
CTO | Chief Tech/Sci/R&D Officer | - | 2025-05-31 |
Robin Wolz
CTO | Chief Tech/Sci/R&D Officer | - | 2020-12-31 |
Tanya Voloshen
PRN | Corporate Officer/Principal | - | 2026-02-04 |
Composition of the Board of Directors: Phytopharm plc
| Director | Title | Age | Since |
|---|---|---|---|
Mark Warne
CHM | Chairman | 51 | - |
Grant Nash
BRD | Director/Board Member | 50 | 2019-08-20 |
Katherine Rogers
BRD | Director/Board Member | 60 | 2022-01-20 |
Dipti Amin
BRD | Director/Board Member | 62 | 2023-10-04 |
Bram Goorden
BRD | Director/Board Member | 53 | 2024-08-18 |
Company details: Phytopharm plc
Other Biotechnology & Medical Research
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.17% | +1.47% | +3.16% | +6.80% | 50.35B | |
| -0.29% | -2.81% | +387.81% | +591.82% | 39.21B | |
| -0.49% | +1.48% | +31.16% | -6.46% | 34.52B | |
| +1.53% | +3.11% | +15.41% | +58.54% | 34.6B | |
| +1.68% | -0.62% | +3.30% | +27.34% | 27.05B | |
| +1.13% | -3.11% | - | - | 16.68B | |
| -1.29% | -0.52% | +69.24% | +117.60% | 15.11B | |
| +0.43% | +3.34% | +14.96% | +17.46% | 13.85B | |
| +2.45% | +3.99% | +18.20% | -30.12% | 13.18B | |
| Average | +0.55% | +0.94% | +67.90% | +97.87% | 27.17B | |
| Weighted average by Cap. | +0.41% | +0.83% | +81.44% | +121.61% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- IXI Stock
- Stock
- Company Phytopharm plc
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
